You have 9 free searches left this month | for more free features.

City

Atlanta (3)

Chapel Hill (1)

New York (1)

Shanghai (1)

Overall Status

Recruiting (3)

Not yet recruiting (1)

Sign in for free

Phase

phase 1 (3)

phase 1/phase 2 (1)

Sponsor

Meryx, Inc. (2)

Betta Pharmaceuticals Co., Ltd. (1)

Emory University (1)

Collaborator

National Cancer Institute (NCI) (1)

Intervention

mrx-2843 (2)

flt3/mertk inhibitor mrx-2843 (1)

mrx2843 (1)

osimertinib (1)

Study Documents

Intervention Type

drug (4)

Funder Type

Industry (3)

Other (1)

Study Type

Interventional (4)

MRX2843

Showing 1 - 4 of 4

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial in Atlanta

Recruiting

Advanced Lung Non-Small Cell Carcinoma
+4 more

Flt3/MerTK Inhibitor MRX-2843
Osimertinib

Atlanta, Georgia

Emory University Hospital/Winship Cancer Institute

Mar 8, 2022

Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia Trial in Atlanta, New York (MRX-2843)

Recruiting

Acute Myeloid Leukemia
+2 more

MRX-2843

Atlanta, Georgia
+2 more

Jul 6, 2022

Advanced Cancer, Metastatic Cancer, Tumors Trial in Atlanta, Chapel Hill (MRX-2843)

Recruiting

Advanced Cancer
+5 more

MRX-2843

Atlanta, Georgia
+1 more

Mar 4, 2022

Acute Myeloid Leukemia Leukemia Trial in Shanghai (MRX2843)

Not yet recruiting

Acute Myeloid Leukemia Leukemia

MRX2843

Shanghai, Shanghai, China

Junmin Li，Ph.D

Jun 23, 2021